BlackRock
ALXO icon

BlackRock’s ALX Oncology ALXO Stock Holding History

BlackRock’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.3M Buy
7,399,530
+6,951,731
+1,552% +$12.4M ﹤0.01% 3444
2026
Q1 		$898K Sell
447,799
-2,631
-0.6% -$5.01K ﹤0.01% 4378
2025
Q4 		$509K Buy
450,430
+2,738
+0.6% +$4.15K ﹤0.01% 4480
2025
Q3 		$819K Sell
447,692
-268,605
-37% -$233K ﹤0.01% 4347
2025
Q2 		$297K Sell
716,297
-1,597,503
-69% -$806K ﹤0.01% 4574
2025
Q1 		$1.44M Sell
2,313,800
-70,447
-3% -$84.6K ﹤0.01% 4088
2024
Q4 		$3.98M Sell
2,384,247
-217,529
-8% -$334K ﹤0.01% 3820
2024
Q3 		$4.74M Sell
2,601,776
-85,843
-3% -$319K ﹤0.01% 3717
2024
Q2 		$16.2M Buy
2,687,619
+466,058
+21% +$5.73M ﹤0.01% 3104
2024
Q1 		$24.8M Sell
2,221,561
-13,532
-0.6% -$190K ﹤0.01% 2866
2023
Q4 		$33.3M Buy
2,235,093
+392,074
+21% +$3.72M ﹤0.01% 2730
2023
Q3 		$8.85M Buy
1,843,019
+54,259
+3% +$294K ﹤0.01% 3407
2023
Q2 		$13.4M Buy
1,788,760
+120,136
+7% +$786K ﹤0.01% 3271
2023
Q1 		$7.54M Sell
1,668,624
-32,462
-2% -$246K ﹤0.01% 3463
2022
Q4 		$19.2M Buy
1,701,086
+30,684
+2% +$345K ﹤0.01% 3058
2022
Q3 		$16M Buy
1,670,402
+8,120
+0.5% +$94.6K ﹤0.01% 3161
2022
Q2 		$13.4M Buy
1,662,282
+306,804
+23% +$3.34M ﹤0.01% 3340
2022
Q1 		$22.9M Buy
1,355,478
+14,907
+1% +$254K ﹤0.01% 3091
2021
Q4 		$28.8M Sell
1,340,571
-26,190
-2% -$1.13M ﹤0.01% 3037
2021
Q3 		$101M Buy
1,366,761
+114,456
+9% +$7.63M ﹤0.01% 2208
2021
Q2 		$68.5M Sell
1,252,305
-266,175
-18% -$15.9M ﹤0.01% 2484
2021
Q1 		$112M Buy
1,518,480
+145,731
+11% +$11.5M ﹤0.01% 2128
2020
Q4 		$118M Buy
1,372,749
+543,735
+66% +$32.7M ﹤0.01% 1978
2020
Q3 		$31.3M Buy
+829,014
New +$32.6M ﹤0.01% 2587

Other funds holding ALXO

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VP
venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

BlackRock's ALXO Position: Q2 2026 in Review

BlackRock increased its ALX Oncology (ALXO) stake by 1,552% in Q2 2026, buying an estimated $12.4M and bringing the position to 7,399,530 shares worth $15.3M. The position accounts for ﹤0.01% of the portfolio, ranked #3444.

BlackRock first reported a position in ALXO in Q3 2020 and has held it in 24 quarters since. The position peaked at $118M in Q4 2020. 93 funds tracked by Wall St. Rank hold ALXO as of Q2 2026.

  • BlackRock held 7,399,530 shares of ALX Oncology worth $15.3M as of Q2 2026.
  • BlackRock bought 6,951,731 ALX Oncology shares in Q2 2026, an estimated $12.4M.
  • ALX Oncology made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #3444 holding.
  • BlackRock first reported a position in ALX Oncology in Q3 2020 and has held it in 24 quarters since.
  • BlackRock's ALX Oncology position peaked at $118M in Q4 2020.
  • 93 funds tracked by Wall St. Rank held ALX Oncology as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.